Cisplatin-induced cardiotoxicity with midrange ejection fraction

Heart Failure and Midrange Ejection Fraction

Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction

BACKGROUND This study aimed to compare the independent and incremental prognostic value of peak oxygen consumption (VO2) and minute ventilation/carbon dioxide production (VE/VCO2) in heart failure (HF) with preserved (HFpEF), midrange (HFmEF), and reduced (HFrEF) ejection fraction (LVEF). METHODS AND RESULTS In 195 HFpEF (LVEF ≥50%), 144 HFmEF (LVEF 40-49%), and 630 HFrEF (LVEF <40%) patients...

Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies.

Increased oxidative stress and apoptosis have been implicated in the cardiotoxicity that limits the clinical use of cisplatin as an anti-tumoral drug. Our study was conducted to evaluate the protective potential of acetyl-l-carnitine, DL-α-lipoic acid and silymarin against cisplatin-induced myocardial injury. Eighty male albino rats were divided into eight groups. The first four groups were tre...

Heart Failure With Preserved Ejection Fraction

The Journal of the American Osteopathic Association July 2015 | Vol 115 | No. 7 432 From Henry Ford Wyandotte Downriver Cardiology in Brownstown, Michigan (Dr Rogers); West Suburban Medical Center in Oak Park, Illinois (Dr Gundala); Oakwood Southshore Medical Center in Trenton, Michigan (Dr Ramos); and Elmhurst Memorial Hospital in Illinois (Dr Serajian). Drs Gundala and Ramos are in their thir...

Heart Failure With Preserved Ejection Fraction

Symptomatic heart failure, despite preserved left ventricular (LV) ejection fraction, is a well-recognized phenomenon. This manifestation of diastolic dysfunction is associated with increased morbidity and mortality and can be attributed to a variety of pathogeneses, including diabetes mellitus, hypertension, infiltrative processes, and obesity. Unlike in systolic heart failure, where LV ejecti...